ArticleCurrent medicinal chemistry2025
New O-alkyl Chalcone Derivative Exhibits Antiproliferative Potential in Colorectal and Cervical Cancer Cells by Inducing G0/G1 Cell Cycle Arrest and Mitochondrial-mediated Apoptosis.
Article in Current medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A novel pyrrolidine-chalcone derivative exhibits synergistic anti-cervical cancer activity by dual-targeting MDM2-p53 axis and ferroptosis pathway.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveThe main objective of the study was to investigate potential anticancer activity in vitro of newly synthesized O-alkyl chalcone derivative (E)-1-(3-metoxy- 4-propoxyphenyl)-5-methylhex-1-en-3-on, (Chalcone 5) on cervical HeLa, colorectal HCT-116 carcinoma cells and healthy MRC-5 cells.
methodsUsing the MTT assay, the cytotoxic effect of Chalcone 5 and reference substances dehydrozingerone and cisplatin were assessed. Using flow cytometry analysis, the labeling process with Annexin V-FITC/7-AAD was carried out to assess the type of cell death, while labeling with PI was used to examine the cell cycle progression in Chalcone 5 treated HeLa and HCT-116 cells. JC-10 probe was used to observe changes in the mitochondrial membrane potential after Chalcone 5 therapy. The expression and cellular localization of the important apoptotic proteins Bcl-2, Bax, caspase 3, and cytochrome c were investigated using flow cytometry and immunofluorescence techniques.
resultsThe treatment of HeLa and HCT-116 cells with Chalcone 5 selectively induced cytotoxicity, and apoptosis and increased the expression of active Bax and caspase-3 while decreasing the expression of Bcl-2, compared to healthy MRC5 cells. Furthermore, Chalcone 5 decreased mitochondrial membrane potential and caused the release of cytochrome c from mitochondria, thereby triggering the mitochondrial inner apoptotic pathway. Moreover, Chalcone 5 arrested cell cycle progression in the G0/G1 phase in both HeLa and HCT-116 cells.
conclusionAccording to the study's findings, Chalcone 5 is a potentially useful candidate drug for additional in vivo research on its anticancer properties against cervical and colon cancer.
Indexed as
Identifiers
40051356What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.